MAYO CLINIC LABORATORIES

1-800-533-1710

RAVU

Ravulizumab, Serum

Patient ID	Patient Name		Birth Date	Gender	Age
SA00141024	SAMPLEREPORT, RAVULIZUMAB		2002-12-12	F	18
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00141024	SA00141024	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		21 Dec 2020 02:02			

Ravulizumab, S

[1] SDL

175.1 mcg/mL

REFERENCE VALUE

Lower limit of quantitation = 5.0 mcg/mL

>175 mcg/mL therapeutic concentration for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)

Received: 21 Dec 2020 06:06 **Reported:** 21 Dec 2020 06:31

Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55901	William G. Morice M.D. Ph.D	24D1040592